Patients and methods: Between 1st January 1998 and 31st December 1999 the incidence and distribution of oral candidial colonization were studied before conditioning and during the aplasia in 80 consecutive allogeneic (29/80) and autologous (51/80) SCT pts. enrolled to the transplantation program. 33 pts. received BM, 43 pts. PBSC and 4 pts. mixed graft. The antimicrobial prophylactic regimen consisted of amoxicillin/clavulanic acid, ciprofloxacin, fluconazol and acyclovir. Anamnestic data of mouth dryness were compared to the results of sialometry, which was performed before conditioning. Mouth swabs for fungal cultures were taken from multiple sites on days -7 and +7. Results: 45/80 (56%) SCT pts. complained of mouth dryness before transplant. The results of sialometry revealed that 15/80 (18%) of patients suffered from objective xerostomy (basal saliva secretion &#61603; 0,1 ml/min) and 28/80 (35%) had relatively decreased basal saliva secretion (0,1-0,2l ml/min). Fungal infection in patients with/without complaining mouth dryness were shown in 7/45 (15,5%) vs.3/35 (8,5%) cases before conditioning and 11/45 (24%) vs. 4/35 (8%) cases during aplasia. In patients with/without complaining mouth dryness solely Candida albicans was isolated in 5/45 (11%) vs. 2/35 (5%), Candida albicans combined with other fungi (C. tropicalis, C. glabrata, C. krusei) in 2/45 (4%) vs. 1/35 (3%) cases before conditioning. During aplasia in patients with/without complaining mouth dryness solely Candida albicans isolates were shown in 7/45 (15,5%) vs. 3/35 (8,5%), Candida albicans combined with other fungi (C. glabrata, C. tropicalis, C. krusei) in 2/45 (4%) vs. 1/35 (3%), and non-Candida fungi in 2/45 (4%) vs. 0/35 (0%) cases. Conclusion: Our examination showed that SCT pts. with pretransplant mouth dryness had higher incidence of Candida albicans and other fungal infections than those of normal saliva secretion, and this difference was even marked between the two examined groups during aplasia. Introduction: Mucosal barrier injury (MBI) of the oral cavity and gut is a severe and dose-limiting complication of the ablative regimens used to prepare for haematopoietic stem cell transplant (HSCT). Gut MBI results in increased permeability and decreased absorption. Currently there are no tools for determining the onset and extent of gut MBI in routine use. Here we describe the changes in gut permeability and absorption as measured by a multi-sugar test. Study population: Six adults received a regimen consisting of idarubicin 42 mg/M2 given by continuous infusion for 48 hours on HSCT day -13 followed by cyclophosphamide 60 mg/kg i.v on days -6 and -5 and total body irradiation with 4.5 Gy on days -2 and -1 in preparation for an HLA-matched, MLC-negative T-cell depleted sibling HSCT. Methods: The multi-sugar probes were tested on HSCT days -13, -7, 0, +7, +14, +21. After an overnight fast, subjects emptied their bladders and then drank an isotonic solution consisting of 5 g lactulose, 1 g L-rhamnose, 0.2 g 3-O-methylglucose, 0.5 g Dxylose in 100 mL. Urine was then collected over 5 h, the total volume was recorded and an aliquot was stored at -80°C. The sugars were detected using high-performance liquid chromatography and the fluorescence label 9-fluorenylmethyl chloroformate hydrazine. Lactulose/rhamnose ratios were used as an index of gut integrity. Results: With respect to baseline (d-12), L/R ratios rose significantly on days 0, +7 and +14 when all patients were profoundly neutropenic indicating altered gut integrity.
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Multi-sugar tests: a tool for measuring gut damage in HSCT recipients?
N.M.A. Blijlevens, B. van ·t Land, J.P. Donnelly, L. M'Rabet, B.E. de Pauw (Nijmegen, Wageningen, NL) Introduction: Mucosal barrier injury (MBI) of the oral cavity and gut is a severe and dose-limiting complication of the ablative regimens used to prepare for haematopoietic stem cell transplant (HSCT). Gut MBI results in increased permeability and decreased absorption. Currently there are no tools for determining the onset and extent of gut MBI in routine use. Here we describe the changes in gut permeability and absorption as measured by a multi-sugar test. Study population: Six adults received a regimen consisting of idarubicin 42 mg/M2 given by continuous infusion for 48 hours on HSCT day -13 followed by cyclophosphamide 60 mg/kg i.v on days -6 and -5 and total body irradiation with 4.5 Gy on days -2 and -1 in preparation for an HLA-matched, MLC-negative T-cell depleted sibling HSCT. Methods: The multi-sugar probes were tested on HSCT days -13, -7, 0, +7, +14, +21. After an overnight fast, subjects emptied their bladders and then drank an isotonic solution consisting of 5 g lactulose, 1 g L-rhamnose, 0.2 g 3-O-methylglucose, 0.5 g Dxylose in 100 mL. Urine was then collected over 5 h, the total volume was recorded and an aliquot was stored at -80°C. The sugars were detected using high-performance liquid chromatography and the fluorescence label 9-fluorenylmethyl chloroformate hydrazine. Lactulose/rhamnose ratios were used as an index of gut integrity. Results: With respect to baseline (d-12), L/R ratios rose significantly on days 0, +7 and +14 when all patients were profoundly neutropenic indicating altered gut integrity.
Conclusion:
This multi-sugar test shows promise as an objective means for detecting and monitoring impaired gut integrity and, hence, gut toxicity.
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Hyperbaric oxygen in the management of severe Haemorrhagic Cystitis (HC) following Stem Cell Transplantation (HCT) I. Sakellari, C. Smias, S. Gavrielides, G. Voskopoulos, M. Marantidou, A. Anagnostopoulos, A. Fassas (Thessaloniki, GR) HC is a multicausal disease and may be associated with significant morbidity post transplantation. Toxic metabolites (acrolein nitric oxide) produced by high doses of cyclophosphamide contribute to hypoxia of the urothelium similar to that post irradiation. Hyperbaric oxygen (HBO) increases the oxygen gradient between the damaged urothelium and the normal adjacent tissues and enhances angiogenesis through the macrophage stimulation. In an effort to successful management of HC, 7 male patients, aged 18 (13-51) years were treated with hyperbaric oxygen combined with local and systematic supportive therapy. They had undergone allogeneic transplant (3 sibling and 4 matched unrelated) for haematological malignancies (3 ALL, 2 leukemic lymphoblastic lymphoma, 1 AML, 1 CML) conditioned with BUCY 2 (BU 16mg/kg, Cy 120mg/kg). HC was diagnosed on day + 55 (32 -89) post transplant and hyperbaric oxygen treatment started 33d after the onset. All patients had clinical significant aGVHD, 6 CMV viremia, 2 CMV viruria. In 2 positive cytomegalovirus consecutive samples. The treatment protocol design predicted patient exposure in the hyperbaric chamber under pressure of 2.2 -2.5 atmospheres for 85 minutes in 20 courses. Finally they underwent 9-32 courses during 11 -59 days under 2.2 -2.5 Atm. 4 out of 7 tolerated treatment well and remitted soon with complete resolution of haematuria and reduced requirement of transfusion support, 2 responded partially but other serious HCT complications imposed the abrupt treatment discontinuation. 20 courses therapy failed in one patient. The timing of the HBO treatment appeared to be critical as the 3 patients who started treatment early after onset responded. Treatment with hyperbaric oxygen seems to have a beneficial durable effect on HC. Early treatment, active, transfusion support treatment against predisposing factors (GVHD, CMV) are crucial. It is a safe and efficacious adjunct therapy deserving further studies. Transplantation of bone marrow or peripheral blood stem cells from an HLA-matched related or unrelated donor is an effective and potentially curative treatment for a variety of malignant hematopoietic disorders. The incidence reported for graft versus host disease (GVHD) grade II to IV after transplantation from HLA matched unrelated donors is 78% and the incidence for grade III and IV is 36%, in spite of the immunosuppressive drugs, CsA, prednisolone and a short course of methotrexate (MTX) used for prevention of GVHD. GvHD of the intestine is associated with mucosal sloughing, diarrhea, hemorrhage, painful spasms, and demonstrates a delayed response to systemic immunsuppressive therapy. Histological descriptions include mucosal denudation, ulcers, edema of the bowel wall, and hemorrhage. We herein report on the results of an ongoing trial to evaluate the potential benefit of Factor XIII replacement in BMT/SCT recipients with GvHD of the bowel. Twenty-two patients have been treated; laboratory investigations include Factor XIII, X; VIII, VII, III, d.dimers, fibrin monomer, and ATIII. Without response to high immunosuppressive therapy, i.e. methylprednisolone 2mg/kg BW per day; mycophenolate mofetil 2 g/day, and IL-2ra treatment, patients received Factor XIII (FibrogaminÔ , CENTEON Pharma GmbH, Germany) replacement 20 IE/kg BW 3 times a day for up to 3 weeks. All pts. suffered from severe bloody diarrhea (Ͼ 6 bloody stools/day) requiring hemoglobin replacement (median: 1 units per day, range: 0.5-2) and severe painful spasms. GvHD involvement of the bowel was confirmed by biopsy. In sixteen patients we observed a reduction of red blood cell transfusion requirement within 8 days of F XIII treatment (median: 0.5 units per day, range: 0.29-2) (p=0.001). Median F XIII levels were 70% (range: 33-105%) before and increased to levels about 141% (range: 87 -209%) (p=0.01) on day 3 and 158% (range: 67-231%) (pϽ0.001) on day 8. We conclude that Factor XIII replacement might be beneficial in severe bowel GvHD in SCT recipients in order to reduce red blood cell transfusion requirement and also to improve the clinical condition of the patients.
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Effect of early administration of high-dose oral glutamine in allogeneic bone marrow transplanted patients M. Picardi, C. Selleri, M. Volpicelli, B. Rotoli (Napoli, I) Glutamine is the most abundant amino acid in human body and represents the metabolic fuel in tissues with high proliferative turnover. We performed a prospective randomized study on the use of glutamine to prevent conditioning regimen (CR)-related damage of rapidly proliferating cell populations (hematopoietic and gastro-intestinal) in allogeneic BMT patients. Eleven adult patients (supplemented group) who received 20 gr oral glutamine daily from 3 days pre-CR until engraftment were compared with 12 patients (unsupplemented group), matched for sex, age, underlying hematological malignant disease, disease status, type of donor (HLA-identical sibling), antimicrobial and acute graft-versus-host disease prophylaxis, and number of CD34+ cells/kg infused. Five (45 %) supplemented patients had severe stomatitis (=/Ͼ grade III) with needs for opiate, compared with 10 (83 %) unsupplemented patients (p= 0.03). Mean duration of stomatitis was 3 (SD 3.3) days in the supplemented vs 7 (SD 4.4) days in the unsupplemented group (p= 0.01); mean opiate use was 3 (SD 2.8) days in the supplemented vs 7 (SD 4.5) days in the unsupplemented group (p= 0.007). Five (45 %) supplemented patients had mouth/gut documented infection compared with 8 (67 %) unsupplemented patients (p= 0.1). One (9 %) supplemented patient received systemic G-/GM-CSF compared with 6 (50 %) unsupplemented patients (p= 0.01); mean growth factor use was 1 (SD 2.4) days in the supplemented and 5 (SD 5.1) days in the unsupplemented group (p= 0.01). No significant difference in diarrhea incidence, total parenteral nutrition use, days to engraftment, acute GVHD and outcome were observed between the two groups. No glutamine-related toxicity occurred in the supplemented group.In conclusion, high-dose oral glutamine supplementation before, during and after CR significantly decreased painful stomatitis and the use of hemopoietic growth factors in allogeneic BMT recipients. A larger prospective, randomized, double-blind, placebo controlled study is needed to confirm this preliminary observation.
